Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Halliburton Company (HAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Halliburton Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.27 (market cap $39.89B), while Halliburton Company trades at $34.65 (market cap $28.73B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Halliburton Company pays a 1.98% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HAL | |
|---|---|---|
Market Cap | $39.89B | $28.73B |
Sector | Health | Energy |
52-Week High | $491.22 | $42.98 |
52-Week Low | $278.09 | $20.50 |
Enterprise Value | $38.15B | $34.81B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Halliburton (HAL) trades at $34.39, up 0.79% with a bullish technical signal. The company shows solid fundamentals with a P/E of 19 and ROE of 14.56%, though recent earnings beat expectations with Q1 2026 EPS of $0.55 versus $0.50 expected. Recent developments include a key Iraq oilfield deal and digital transformation partnerships, supporting growth prospects in the oil services sector.
Outlook remains positive with analyst consensus price target of $44.00 (28% upside), though risks include oil price volatility and execution challenges. Revenue stability around $22B and strong cash flow generation provide fundamental support, while technical indicators suggest potential resistance near $35.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
